Business Wire

Skilling lanserar branschens första sömlösa integration med Spotwares cTrader, inriktad på erfarna handlare.

Share

Forex- och CFD-handelsplattformen Skilling annonserade förra veckan lanseringen av branschens första sömlösa integration med Spotwares cTrader - en unik funktion som internt kallas Ett konto. Två plattformar.

Detta pressmeddelande använder multimedia. Se den fullständiga versionen här: https://www.businesswire.com/news/home/20200130005070/sv/

Skilling lanserar branschens första sömlösa integration med Spotwares cTrader. (Photo: Business Wire)

Skilling lanserar branschens första sömlösa integration med Spotwares cTrader. (Photo: Business Wire)

Funktionen gör att Skilling kan erbjuda sina kunder sömlös handel över två olika handelsplattformar på ett enda Skilling-konto utan att behöva finansiera och hantera två olika konton separat.

”Enkelt uttryckt ville vi ge våra kunder valet vilken handelsplattform de kan använda - vår egen Skilling Trader eller en mer avancerad klientorienterad cTrader. Problemet du har med andra mäklare som erbjuder flera plattformar är behovet av att finansiera två konton separat, upprätthålla sunda marginaler på två olika konton och också ha två uppsättningar av aktiviteter. Med denna unika integration - allt du gör i en handelsplattform kommer också att återspeglas i den andra. Så om du börjar handla med guld på Skilling Trader ser du samma position när du använder vår cTrader-plattform. Och vice versa. Hej då till två olika Tillgängliga kontanter, två Kontovärden och två Handelskonton. Med Skilling kommer du att ha ett enda handelskonto och ett val genom vilken plattform du kan utföra dina affärer,” säger André Lavold, VD för Skilling Group.

Denna funktion följer en serie innovationer som Skilling nyligen har lanserat, inklusive lanseringen av sin nya mobilapp tidigare i år.

”Vi har en spännande färdplan för produkt- och affärsutveckling nu när vi går in i 2020, och både jag och teamet är mycket entusiastiska över vad som ligger framöver,” tillägger Lavold.

Om Skilling

Skilling är en online-handelsplattform som erbjuder handel med forex och CFD på instrument från marknader runt om i världen. Visionen är att låsa upp världens finansmarknader genom att göra handel enkel och tillgänglig för alla i en transparent och säker miljö. Forex och CFD, inklusive kryptovalutor, index, aktier och råvaror kan alla handlas på Skillings handelsplattform, utformad för att vara enkel, tillgänglig och transparent.

Skilling Ltd är ett värdepappersföretag, auktoriserat och reglerat av Cyprus Securities and Exchange Commission (CIF-licens nr 357/18).

För mer information, gå till skilling.com/eu/sv

73% av retail kunder förlorar pengar.

Contact information

För mer information, kontakta:
Pavel Spirin
marketing@skilling.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mobidiag Offers Complete Diagnostic Solution for the Detection of Novel Coronavirus Infections with Both PCR and Antibody Tests2.6.2020 06:00:00 CESTPress release

Mobidiag Ltd., a revenue generating, molecular diagnostics company with complementary platforms that address infectious diseases, antimicrobial resistance and other areas of unmet diagnostic need, today announces that it has received CE-IVD markings for its https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fmobidiag.com%2Fproducts%2Fcoronavirus-1%2F%23Novodiag-COVID-19&esheet=52228608&newsitemid=20200601005614&lan=en-US&anchor=Novodiag%26%23174%3B+COVID-19&index=1&md5=a6f8720fcb65487af8166329d2b56957 Novodiag® COVID-19 and https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fmobidiag.com%2Fproducts%2Fcoronavirus-1%2F%23Amplidiag-COVID-19&esheet=52228608&newsitemid=20200601005614&lan=en-US&anchor=Amplidiag%26%23174%3B+COVID-19&index=2&md5=3dc50805e09ec072bce2a6e5aa75368a Amplidiag® COVID-19 molecular diagnostic tests for the early detection of the SARS-CoV-2 virus, responsible for novel coronavirus infection (COVID-19). These tests complement the Company’s al

Newmont Publishes 2019 Sustainability Report1.6.2020 15:00:00 CESTPress release

Newmont Corporation (NYSE: NEM, TSX: NGT) (Newmont or The Company) today announced the publication of its 2019 Sustainability Report, Beyond the Mine, a transparent and comprehensive disclosure of the Company’s environmental, social and governance (ESG) performance. “Our sustainability report provides investors and other stakeholders a transparent and detailed look at look at our safety, environmental and social performance,” said Tom Palmer, President and Chief Executive Officer. “In 2019, we completed two transformative transactions whilst enhancing our ESG performance to align with our position as the world’s leading gold company.” Newmont’s 2019 sustainability highlights include: Achieving no workplace fatalities and conducting a global safety culture review, which identified several opportunities to enhance Newmont’s Fatality Risk Management program and improve the way fatality risks are managed Further strengthening management of tailings, whilst enhancing transparency through a

New Western Union research provides insight into the future of international education1.6.2020 15:00:00 CESTPress release

The Western Union Company (NYSE: WU), a leader in cross-border, cross-currency money movement and payments, today shares a new report on “The Future of International Education,” in partnership with The Future Laboratory. The white paper highlights five new student profiles that will evolve from the shifting attitudes and behaviors of today’s youth. From Hybrid Thinkers to Greener Graduates, this new report predicts how academic institutions should adapt to meet these expectations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200601005162/en/ Meet the students of the future: new student profiles uncovered in “The Future of International Education” (Graphic: Business Wire) The findings come as universities and colleges worldwide are evolving to navigate COVID-19, from moving online, to delaying term dates. Institutions can use the report to ensure the new policies they introduce align with the needs and priorities of interna

Vivet’s Second Gene Therapy Product, VTX-803 for PFIC3, Receives US and European Orphan Drug Designation1.6.2020 13:00:00 CESTPress release

Vivet Therapeutics announced today that both the Food and Drug Administration (FDA) and the European Commission (EC) have granted Orphan Drug Designation (ODD) for Vivet’s second gene therapy product, VTX-803, for the treatment of Progressive Familial Intrahepatic Cholestasis type 3 (PFIC3). PFIC3 is a rare life-threatening and chronically debilitating condition due to progressive severe liver dysfunction, accompanied by jaundice, portal hypertension, hepatosplenomegaly and failure to thrive. The symptoms of the disease usually appear first in childhood with progressive cholestasis, evolving to hepatic failure, cirrhosis and need for liver transplantation. “We are very pleased to receive these designations which further validate Vivet’s efforts to treat rare inherited metabolic disorders. The FDA and EC have both recognized the unmet need for a safe and effective treatment of PFIC3 and the potential of VTX-803 to address such need. The field of Progressive Familial Intrahepatic Cholest

FDA Issues Emergency Use Authorization for Impella RP as Therapy for COVID-19 Patients with Right Heart Failure1.6.2020 13:00:00 CESTPress release

The United States Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for Impella RP to include patients suffering from COVID-19 related right heart failure or decompensation, including pulmonary embolism (PE). Abiomed (NASDAQ: ABMD) manufactures Impella RP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200601005257/en/ Impella RP is now FDA indicated for COVID-19 related complications, including pulmonary embolism. (Photo: Business Wire) Impella RP is a temporary heart pump that provides circulatory support for patients who develop right side ventricular failure. Five years of pre- and post-market clinical studies support Impella RP’s safety and efficacy. In 2017, Impella RP received FDA approval as safe and effective for treating right ventricular failure in the setting of acute myocardial infarction and after cardiac surgery. Biventricular cardiac support can be provided when Impella RP is

Zynga Enters Into Agreement to Acquire Istanbul-based Peak, Creator of Top Charting Mobile Franchises Toon Blast and Toy Blast1.6.2020 13:00:00 CESTPress release

Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, today announced it has entered into a definitive agreement to acquire Peak, one of the most globally successful mobile gaming companies, for $1.8 billion. Peak brings a 100-person strong team and two Forever Franchises, Toon Blast and Toy Blast, that have consistently ranked in the top 10 and top 20 U.S. iPhone grossing games for over two years, respectively. These franchises add significant scale to Zynga’s live services and will be an additional driver of margin expansion over the coming years. Peak also enhances Zynga’s new game pipeline with additional projects in early development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200601005142/en/ Zynga Enters Into Agreement to Acquire Istanbul-based Peak, Creator of Top Charting Mobile Franchises Toon Blast and Toy Blast (Graphic: Business Wire) Founded in 2010 by Sidar Sahin, Peak has developed the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom